ARROWHEAD PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation Fdii Percent
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Effective Income Tax Rate Reconciliation Fdii Percent of 16.20% for the 12-month period ending 2025-09-30, per its 10-K filed 2025-11-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent · last filed 2025-11-25
- ARROWHEAD PHARMACEUTICALS, INC. effective income tax rate reconciliation fdii percent for fiscal 2025 was 16.20%.
- ARROWHEAD PHARMACEUTICALS, INC. effective income tax rate reconciliation fdii percent for fiscal 2024 was 0.00%.
- ARROWHEAD PHARMACEUTICALS, INC. effective income tax rate reconciliation fdii percent for fiscal 2023 was -1.20%.
- ARROWHEAD PHARMACEUTICALS, INC. effective income tax rate reconciliation fdii percent for fiscal 2022 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation Fdii Percent 12 month | Effective Income Tax Rate Reconciliation Fdii Percent 12 month as first filed |
|---|---|---|
| 2025-09-30 | 16.20% 10-K · filed 2025-11-25 | |
| 2024-09-30 | 0.00% 10-K · filed 2025-11-25 | |
| 2023-09-30 | -1.20% 10-K · filed 2025-11-25 | 1.20% 10-K · filed 2023-11-29 |
| 2022-09-30 | 0.00% 10-K · filed 2024-11-26 | |
| 2021-09-30 | 0.00% 10-K · filed 2023-11-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |